The poor prognosis associated with gain/amplification of 1q21
in relapsed multiple myeloma patients may be overcome by
Velcade based regimen in contrary of thalidomide based regimen

a 2008

The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen

NĚMEC, Pavel; Henrieta GREŠLIKOVÁ; Jan SMETANA; Romana ZAORALOVÁ; Renata KUPSKÁ et. al.

Basic information

Original name

The poor prognosis associated with gain/amplification of 1q21 in relapsed multiple myeloma patients may be overcome by Velcade based regimen in contrary of thalidomide based regimen

Name in Czech

Nepříznivá prognóza zisku1q21 u relabovaných pacientů s mnohočetným myelomem může být překonán léčbou založenou na Velcade narozdíl od léčby založené na podávání thalidomidu

Authors

NĚMEC, Pavel; Henrieta GREŠLIKOVÁ; Jan SMETANA; Romana ZAORALOVÁ; Renata KUPSKÁ; Kristina BERÁNKOVÁ; Hana FILKOVÁ; Dana KRÁLOVÁ; Marta KREJČÍ; Luděk POUR; Lenka ZAHRADOVÁ; Viera SANDECKÁ; Zdeněk ADAM; Petr KUGLÍK and Roman HÁJEK

Edition

Haematologica/The Hematology Journal, 2008

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

is not subject to a state or trade secret

Impact factor

Impact factor: 5.978

Organization unit

Faculty of Medicine

ISSN

UT WoS

000263430200562

Keywords in English

multiple myeloma; Velcade; thalidomide

Abstract

ORIG CZ

In the original language

This study is aimed at comparison of ability to overcome the negative prognostic impact of the most common cytogenetic aberrations by treatment regimens based on Velcade or thalidomide. Both new drugs can overcome negative prognostic impact of all named chromosomal abnormalities except Amp1q21. The difference in TTP median in Amp1q21 positive and negative patients treated by thalidomide based regimen suggests that thalidomide is not able to overcome negative prognostic impact of Amp1q21 in contrary of treatment based on Velcade regimen, which probably may overcome poor prognosis of Amp1q21.

In Czech

Práce pojednáva o schopnosti léčby založené na podávání Velcade nebo thalidomidu překonat nepříznivý vliv zisku 1q21 u relabovaných pacientů s mnohočetným myelomem.

Links

LC06027, research and development project

Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)

Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group

MSM0021622415, plan (intention)

Name: Molekulární podstata buněčných a tkáňových regulací

Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations

MSM0021622434, plan (intention)

Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

NR9317, research and development project

Name: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu

Přehled o publikaci